In December 2019, a novel coronavirus was isolated from the respiratory epithelium of
patients with unexplained pneumonia in Wuhan, China. This pathogen, named severe acute …

Antibody-dependent enhancement (ADE) of disease is a general concern for the
development of vaccines and antibody therapies because the mechanisms that underlie …

Antibodies elicited by infection accumulate somatic mutations in germinal centers that can
increase affinity for cognate antigens. We analyzed 6 independent groups of clonally related …

Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future
protection of individuals and populations against SARS-CoV-2. Moreover, passively …

The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein mediates viral
attachment to ACE2 receptor and is a major determinant of host range and a dominant target …

Antibodies targeting the spike protein of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) present a promising approach to combat the coronavirus disease 2019 …

The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has resulted in more than 28,000,000 infections and 900,000 …

Convalescent plasma is a leading treatment for coronavirus disease 2019 (COVID-19), but
there is a paucity of data identifying its therapeutic efficacy. Among 126 potential …

Coronaviruses are prone to transmission to new host species, as recently demonstrated by
the spread to humans of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Antibodies are a principal determinant of immunity for most RNA viruses and have promise
to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 …